IL159238A - Crystalline anticholinergic, method for its production and use thereof in the production of a drug - Google Patents
Crystalline anticholinergic, method for its production and use thereof in the production of a drugInfo
- Publication number
- IL159238A IL159238A IL159238A IL15923803A IL159238A IL 159238 A IL159238 A IL 159238A IL 159238 A IL159238 A IL 159238A IL 15923803 A IL15923803 A IL 15923803A IL 159238 A IL159238 A IL 159238A
- Authority
- IL
- Israel
- Prior art keywords
- tiotropium bromide
- crystalline
- anhydrous
- production
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to crystalline, water-free (1 alpha ,2 beta ,4 beta ,5 alpha ,7 beta )-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0<2,4>]nonane-bromide, to a method for its production, and to the use thereof in the production of a drug, especially in the production of an anticholinergic drug.
[WO03000265A1]
Claims (10)
1. 59238/2 19 78190amd.209^r Amended claims V 1 ) Anhydrous crystalline tiotropium bromide, characterised by a monoclinic elementary cell with the parameters a = 10.4336(2)A, b = 11 .3297(3)A, c = 17.6332(4) A, a = 90°, β = 105.158(2)° and λ = 90° (cell volume=201 1.89(8) A3) determined by X-ray structural analysis.
2. ) Process for preparing crystalline, anhydrous tiotropium bromide according to claim 1, characterized in that it is prepared by careful drying of monohydrate tiotropium bromide at more than 50°C, preferably at 60-100°C, under reduced pressure.
3. ) Process according to claim 2, characterised in that the drying is carried out over a period of from 15 minutes to 24 hours.
4. ) Process for preparing crystalline, anhydrous tiotropium bromide, according to claim 1 , characterised in that it is prepared by storing crystalline tiotropium bromide monohydrate over a suitable drying agent for a period of 12 to 96 hours.
5. ) Crystalline anhydrous tiotropium bromide, obtainable according to one of claims 2, 3 or 4.
6. ) Pharmaceutical composition, characterised in that it contains crystalline anhydrous tiotropium bromide according to one of claims 1 or 5.
7. ) Pharmaceutical composition according to claim 6, characterised in that it is an inhalable powder.
8. ) Inhalable powder according to claim 7, characterised in that it contains crystalline anhydrous tiotropium bromide according to claim 1 or 5 in admixture with a physiologically acceptable excipient.
9. ) Inhalable powder according to claim 8, characterised in that the excipient is selected from the group consisting of glucose and lactose.
10. ) Use of crystalline anhydrous tiotropium bromide according to one of claims 1 or 5 for preparing a pharmaceutical composition for the treatment of diseases in which the administration of an anticholinergic may have a therapeutic benefit. 1 Use according to claim 10, characterised in that the diseases are asthma or COPD. For th© Applicants MOID COHM AND PABINBS
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129710 | 2001-06-22 | ||
| DE10215436 | 2002-04-08 | ||
| PCT/EP2002/006291 WO2003000265A1 (en) | 2001-06-22 | 2002-06-08 | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL159238A true IL159238A (en) | 2010-04-15 |
Family
ID=26009556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15923802A IL159238A0 (en) | 2001-06-22 | 2002-06-08 | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
| IL159238A IL159238A (en) | 2001-06-22 | 2003-12-08 | Crystalline anticholinergic, method for its production and use thereof in the production of a drug |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15923802A IL159238A0 (en) | 2001-06-22 | 2002-06-08 | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1401445B1 (en) |
| JP (1) | JP2005504015A (en) |
| KR (2) | KR100971616B1 (en) |
| CN (1) | CN100586948C (en) |
| AR (1) | AR037491A1 (en) |
| AT (1) | ATE337006T1 (en) |
| AU (1) | AU2002345016B2 (en) |
| BG (1) | BG66303B1 (en) |
| BR (1) | BR0210537A (en) |
| CA (1) | CA2450961C (en) |
| CO (1) | CO5550423A2 (en) |
| CY (1) | CY1105223T1 (en) |
| CZ (1) | CZ302786B6 (en) |
| DE (1) | DE50207943D1 (en) |
| DK (1) | DK1401445T3 (en) |
| EA (1) | EA005813B1 (en) |
| EE (1) | EE05316B1 (en) |
| EG (1) | EG24851A (en) |
| ES (1) | ES2271280T3 (en) |
| HK (1) | HK1068540A1 (en) |
| HR (1) | HRP20031066B1 (en) |
| HU (1) | HUP0400333A3 (en) |
| IL (2) | IL159238A0 (en) |
| ME (1) | ME00412B (en) |
| MX (1) | MXPA03011718A (en) |
| MY (1) | MY122779A (en) |
| NO (1) | NO334301B1 (en) |
| NZ (1) | NZ530690A (en) |
| PE (2) | PE20081305A1 (en) |
| PL (1) | PL208137B1 (en) |
| PT (1) | PT1401445E (en) |
| RS (1) | RS50441B (en) |
| SA (1) | SA02230255B1 (en) |
| SI (1) | SI1401445T1 (en) |
| SK (1) | SK287262B6 (en) |
| TW (2) | TW200617007A (en) |
| UY (1) | UY27342A1 (en) |
| WO (1) | WO2003000265A1 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10212264A1 (en) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US20050038004A1 (en) * | 2003-07-31 | 2005-02-17 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| ATE453641T1 (en) * | 2003-11-03 | 2010-01-15 | Boehringer Ingelheim Int | NEW CRYSTALLINE ANHYDRATE WITH ANTICHOLINER EFFECTIVENESS |
| DE102004016179A1 (en) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Compounds for the treatment of proliferative processes |
| EP2422786B1 (en) | 2004-04-22 | 2014-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | New medicine combinations for treating respiratory diseases |
| DE102004024454A1 (en) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| DE602004020337D1 (en) | 2004-08-11 | 2009-05-14 | Boehringer Ingelheim Pharma | Anticholinergic drugs for the treatment of urinary tract disorders |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| DE102004048389A1 (en) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Modification of surfaces of lactose as adjuvant for use with powder inhalants |
| KR20080007645A (en) | 2005-04-28 | 2008-01-22 | 베링거 인겔하임 인터내셔날 게엠베하 | Novel compounds for treating inflammatory diseases |
| NZ563596A (en) * | 2005-05-02 | 2011-01-28 | Boehringer Ingelheim Int | Crystalline form of tiotropium bromide anhydrate |
| AU2006243239A1 (en) * | 2005-05-02 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Crystalline forms of tiotropium bromide |
| DE102005030733A1 (en) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New drug combinations for the treatment of respiratory diseases containing long-acting beta-2 agonists and at least one other active ingredient |
| WO2007020227A1 (en) | 2005-08-15 | 2007-02-22 | Boehringer Ingelheim International Gmbh | Method for producing betamimetics |
| US20070086957A1 (en) | 2005-10-10 | 2007-04-19 | Thierry Bouyssou | Combination of medicaments for the treatment of respiratory diseases |
| US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
| MX2007009988A (en) * | 2005-12-19 | 2008-02-22 | Sicor Inc | Novel forms of tiotropium bromide and processes for preparation thereof. |
| US9108962B2 (en) | 2005-12-19 | 2015-08-18 | Sicor, Inc. | Forms of tiotropium bromide and processes for preparation thereof |
| CN100999521B (en) * | 2006-01-13 | 2010-12-08 | 江苏正大天晴药业股份有限公司 | Crystal anti-choline medicine thiatropic bromoammonium |
| EP1847543A1 (en) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| NZ563488A (en) | 2006-04-19 | 2010-04-30 | Boehringer Ingelheim Int | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| JP2010500318A (en) | 2006-08-07 | 2010-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical composition for the treatment of respiratory diseases |
| PE20080610A1 (en) | 2006-08-22 | 2008-07-15 | Boehringer Ingelheim Int | NEW ENANTHOMERICALLY PURE BETA-AGONISTS, PROCEDURES FOR THEIR PREPARATION AND USE AS MEDICINES |
| GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| WO2009050248A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
| EP2093219A1 (en) | 2008-02-22 | 2009-08-26 | Boehringer Ingelheim International Gmbh | Crystalline enantiomer free salt form of a betamimetic and its use as medicine |
| US20120053164A1 (en) | 2008-12-19 | 2012-03-01 | Boehringer Ingelheim International Gmbh | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
| EP2403851B1 (en) | 2009-03-06 | 2015-06-17 | Mahmut Bilgic | New crystalline forms of tiotropium bromide |
| GEP20146124B (en) | 2009-12-17 | 2014-07-25 | Boehringer Ingelheim Int | Novel ccr2 receptor antagonists and usage thereof |
| EP2513086B1 (en) | 2009-12-17 | 2015-04-29 | Boehringer Ingelheim International GmbH | Novel antagonists for ccr2 and uses thereof |
| EA201201052A1 (en) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | SUBSTITUTED NAFTYRIDINE AND THEIR APPLICATION AS KINASE SYK INHIBITORS |
| US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP2013526507A (en) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | NOVEL CCR2 RECEPTOR ANTAGONIST, PROCESS FOR PRODUCING THE SAME AND USE THEREOF AS DRUG |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| JP5636094B2 (en) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CCR2 receptor antagonist |
| WO2011151251A1 (en) | 2010-06-01 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New ccr2 antagonists |
| TR201007108A2 (en) * | 2010-08-25 | 2012-03-21 | B�Lg�� Mahmut | New tiotropium bromide crystal and production method. |
| JP5959537B2 (en) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Substituted pyridinyl-pyrimidines and their use as pharmaceuticals |
| TR201101897A2 (en) | 2011-02-28 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Crystal material containing tiotropium bromide |
| TR201102068A2 (en) | 2011-03-03 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Crystalline substances containing tiotropium bromide |
| TR201111589A2 (en) * | 2011-03-03 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Tiotropium bromide anhydrous crystal form. |
| WO2012171863A1 (en) | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| JP5860960B2 (en) | 2011-07-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Substituted quinolines and their use as pharmaceuticals |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| PE20190181A1 (en) | 2011-11-25 | 2019-02-01 | Adverio Pharma Gmbh | PROCEDURE FOR THE PREPARATION OF 5-FLUORO-1H-PYRAZOLOPYRIDINES SUBSTITUTED |
| CZ304368B6 (en) | 2011-11-28 | 2014-04-02 | Zentiva, K.S. | Tiotropium bromide mixed solvate and process for preparing thereof |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| PT106142B (en) * | 2012-02-10 | 2014-07-18 | Hovione Farmaci Ncia S A | PROCESS FOR THE PREPARATION OF TIOTROPE BROMIDE |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| WO2014042605A1 (en) * | 2012-09-11 | 2014-03-20 | Mahmut Bilgic | New tiotropium bromide crystalline form |
| BR112015009654A2 (en) | 2012-11-05 | 2017-07-04 | Zentiva Ks | methods for stabilizing tiotropium bromide micronized or ground solvates and preparing tiotropium bromide solvate, tiotropium bromide solvate, and use of stabilized solvates |
| CN104341412A (en) * | 2013-07-29 | 2015-02-11 | 天津金耀集团有限公司 | Anhydrous tiotropium bromide crystal preparation method |
| LT3119772T (en) | 2014-03-19 | 2019-08-26 | Boehringer Ingelheim International Gmbh | Heteroaryl syk inhibitors |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| WO2016065028A1 (en) | 2014-10-21 | 2016-04-28 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine |
| WO2017138896A1 (en) * | 2016-02-11 | 2017-08-17 | Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti | Crystalline form of tiotropium bromide anhydrate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931041C2 (en) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them |
| AU2002214996B2 (en) * | 2000-10-12 | 2007-03-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| DE10064816A1 (en) * | 2000-12-22 | 2002-06-27 | Boehringer Ingelheim Pharma | Production of tiotropium bromide useful as an anticholinergic comprises oxidation of di-(2-thienyl)-glycolic acid tropenol ester and subsequent quaternisation |
-
2002
- 2002-06-08 ME MEP-2008-620A patent/ME00412B/en unknown
- 2002-06-08 CA CA2450961A patent/CA2450961C/en not_active Expired - Fee Related
- 2002-06-08 DK DK02743165T patent/DK1401445T3/en active
- 2002-06-08 MX MXPA03011718A patent/MXPA03011718A/en active IP Right Grant
- 2002-06-08 PT PT02743165T patent/PT1401445E/en unknown
- 2002-06-08 ES ES02743165T patent/ES2271280T3/en not_active Expired - Lifetime
- 2002-06-08 SK SK52-2004A patent/SK287262B6/en unknown
- 2002-06-08 HU HU0400333A patent/HUP0400333A3/en unknown
- 2002-06-08 AT AT02743165T patent/ATE337006T1/en active
- 2002-06-08 PL PL364489A patent/PL208137B1/en unknown
- 2002-06-08 NZ NZ530690A patent/NZ530690A/en not_active IP Right Cessation
- 2002-06-08 JP JP2003506910A patent/JP2005504015A/en active Pending
- 2002-06-08 KR KR1020037016769A patent/KR100971616B1/en active IP Right Grant
- 2002-06-08 BR BR0210537-3A patent/BR0210537A/en active Pending
- 2002-06-08 AU AU2002345016A patent/AU2002345016B2/en not_active Expired
- 2002-06-08 DE DE50207943T patent/DE50207943D1/en not_active Expired - Lifetime
- 2002-06-08 CN CN02812303A patent/CN100586948C/en not_active Expired - Lifetime
- 2002-06-08 EE EEP200400029A patent/EE05316B1/en unknown
- 2002-06-08 WO PCT/EP2002/006291 patent/WO2003000265A1/en active Application Filing
- 2002-06-08 CZ CZ20040120A patent/CZ302786B6/en not_active IP Right Cessation
- 2002-06-08 EP EP02743165A patent/EP1401445B1/en not_active Expired - Lifetime
- 2002-06-08 EA EA200301293A patent/EA005813B1/en not_active IP Right Cessation
- 2002-06-08 KR KR1020097004823A patent/KR101011353B1/en active IP Right Grant
- 2002-06-08 SI SI200230431T patent/SI1401445T1/en unknown
- 2002-06-08 IL IL15923802A patent/IL159238A0/en unknown
- 2002-06-08 RS YUP-997/03A patent/RS50441B/en unknown
- 2002-06-19 EG EG2002060698A patent/EG24851A/en active
- 2002-06-19 TW TW095100968A patent/TW200617007A/en unknown
- 2002-06-19 TW TW091113373A patent/TWI261589B/en not_active IP Right Cessation
- 2002-06-20 MY MYPI20022316A patent/MY122779A/en unknown
- 2002-06-20 UY UY27342A patent/UY27342A1/en not_active Application Discontinuation
- 2002-06-21 PE PE2007000660A patent/PE20081305A1/en not_active Application Discontinuation
- 2002-06-21 AR ARP020102337A patent/AR037491A1/en not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 2002-06-21 PE PE2002000538A patent/PE20030130A1/en active IP Right Grant
- 2002-08-19 SA SA2230255A patent/SA02230255B1/en unknown
-
2003
- 2003-12-08 IL IL159238A patent/IL159238A/en active IP Right Grant
- 2003-12-12 BG BG108440A patent/BG66303B1/en active Active
- 2003-12-19 NO NO20035696A patent/NO334301B1/en not_active IP Right Cessation
- 2003-12-19 HR HR20031066A patent/HRP20031066B1/en not_active IP Right Cessation
-
2004
- 2004-01-20 CO CO04003764A patent/CO5550423A2/en not_active Application Discontinuation
-
2005
- 2005-01-29 HK HK05100780.9A patent/HK1068540A1/en not_active IP Right Cessation
-
2006
- 2006-09-20 CY CY20061101339T patent/CY1105223T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL159238A (en) | Crystalline anticholinergic, method for its production and use thereof in the production of a drug | |
| US7078412B2 (en) | Quinuclidine derivatives and medicinal compositions containing the same | |
| CA2440699C (en) | Compounds for treating inflammatory diseases | |
| AU2002227910B2 (en) | Novel medicament compositions based on tiotropium salts and on salmeterol salts | |
| US20040019073A1 (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
| AU2002257587B2 (en) | Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors | |
| US20020111363A1 (en) | Inhalable formulation of a solution containing a tiotropium salt | |
| RU2325388C2 (en) | New anticholinergic preparations, method of their production and their application as pharmaceuticals | |
| NZ522677A (en) | Novel, slow-acting betamimetics, a method for their production and their use as medicaments | |
| US20020193393A1 (en) | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors | |
| US20040266869A1 (en) | Novel medicament compositions based on anticholinesterase drugs and on ciclesonides | |
| AU2003232201B2 (en) | Medicaments containing betamimetic drugs and a novel anticholinesterase drug | |
| MXPA01011400A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics. | |
| JP2007517827A (en) | Use of substituted pyrimido [5,4-d] pyrimidines for the treatment of respiratory diseases | |
| JP2007517827A6 (en) | Use of substituted pyrimido [5,4-d] pyrimidines for the treatment of respiratory diseases | |
| JPH06234635A (en) | Use of leflunomide for inhibiting interleukin-1 beta | |
| US20170202858A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| EP2091537B1 (en) | Pharmaceutical compositions for the treatment of capillary arteriopathy | |
| JP2007524699A (en) | Combination of roflumilast and glycopyrronium | |
| AU2003222791B2 (en) | Aerosol formulation for inhalation comprising a tiotropium salt | |
| US20030203918A1 (en) | Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound | |
| US20020193394A1 (en) | Compounds for treating inflammatory diseases | |
| MXPA05005443A (en) | Carbamic acid esters with an anticholinergic action. | |
| EP2566449B1 (en) | Pharmaceutical compositions comprising ceftibuten | |
| AU2003216921B2 (en) | Medicaments containing steroids and a novel anticholinesterase drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |